In re Celgene Corporation, Inc. Securities Litigation

Summary

The United States District Court for the District of New Jersey grants preliminary approval of a proposed $239 million settlement in a securities class action involving Celgene Corporation. The court finds that extensive discovery, arms-length negotiations, and litigation risks support preliminary approval, but withholds approval of the proposed notice materials and settlement hearing schedule. The court directs the plaintiff to revise the claims form and related materials to make them more accessible to retail investors and potential objectors.

Holdings

1. Preliminary approval was warranted because the settlement followed extensive discovery, investigation, expert analysis, and arm's-length mediation, and the settlement amount realistically reflected substantial risks concerning liability and damages.
2. The court would not authorize dissemination or schedule the settlement hearing until the plaintiff substantially revised the proposed claims form and related materials to make participation and claims submission clear, simple, and accessible.

Questions Presented

1. Whether the proposed class-action settlement should receive preliminary approval under Federal Rule of Civil Procedure 23(e).
2. Whether the proposed notice, claims form, and related settlement materials were sufficiently clear and accessible to authorize dissemination and schedule a final settlement-approval hearing.

Disposition

other